business.financialpost.com
Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer
MIRAMAR, Fla. — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) ( today announced that the Company filed an investigational new drug application (IND) with the U.S. Food & Drug…